ArticleHemaSphere2024
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Article in HemaSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Spatial pattern-driven interpretable model and biological correlates in brain glioblastoma-lymphoma differentiation.iScience · 2026Article
- Berubicin Substituted for Cytarabine in a MATRix-Based Regimen for Isolated Central Nervous System Lymphoma: A Five-Patient Case Series from the BER-PUM Study.Current oncology (Toronto, Ont.) · 2026Article
- Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa-Based Regimen in Newly Diagnosed Primary CNS Lymphoma.International journal of cancer · 2026Article
- MRI Deep Learning for Differentiating Glioblastoma, IDH Wild-type from Central Nervous System Diffuse Large B-cell Lymphoma.Cancer research communications · 2026Article
- Article
- Translating advances in primary central nervous system lymphoma: from prognostic stratification to treatment innovation.Frontiers in oncology · 2026Review
- Case Report: Cerebellar ALK+ ALCL: diagnostic challenges and therapeutic innovation.Frontiers in oncology · 2026Article
- Article
- Length of hospital stay and outcome in primary central nervous system lymphoma: a French retrospective multicentric study.Annals of hematology · 2025Article
- Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi Era.International journal of molecular sciences · 2025Review
- Successful treatment of primary intramedullary spinal cord lymphoma based on the molecular diagnosis of a MYD88 mutation in the cerebrospinal fluid: a case report.International cancer conference journal · 2025Article
- Outcomes of primary CNS lymphoma treated with combined immunochemotherapy with whole-brain radiotherapy.Annals of hematology · 2025Article
- [Staging and treatment response assessment with radiological and nuclear medicine approaches for non-Hodgkin lymphomas].Radiologie (Heidelberg, Germany) · 2025Review
- Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma.Haematologica · 2025Article
- Post-marketing surveillance of tirabrutinib in 189 patients with r/r primary central nervous system lymphoma.Future oncology (London, England) · 2025Observational
- Guiding clinical management of patients with CNS lymphomas by minimal-invasive detection of ctDNA in cerebrospinal fluid.Leukemia · 2025Article
- Primary Central Nervous System B-Cell Lymphoma Presenting with Fluctuating Basal Ganglia and Cortical Lesions.Journal of the Belgian Society of Radiology · 2025Article
- Intraoperative classification of CNS lymphoma and glioblastoma by AI-based analysis of Stimulated Raman Histology (SRH).Brain & spine · 2025Article
- Consolidation therapy impact on survival outcomes in young patients with intracranial primary diffuse large B-cell lymphoma achieving complete remission: a propensity score matching analysis.Frontiers in oncology · 2025Article
- In the era of targeted therapy and immunotherapy: advances in the treatment of large B-cell lymphoma of immune-privileged sites.Frontiers in immunology · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This EHA-ESMO Clinical Practice Guideline provides key recommendations for managing primary DLBCL of the CNS.The guideline covers clinical, imaging and pathological diagnosis, staging and risk assessment, treatment and follow-up.Algorithms for first-line and salvage treatments are provided.The author group encompasses a multidisciplinary group of experts from different institutions and countries in Europe.Recommendations are based on available scientific data and the authors' collective expert opinion.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.